Gynecologic Oncology 140 (2016) 259–263

Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno

Research Paper

Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance

Bernadette M. Boac [a], Yin Xiong [a,b], Douglas C. Marchion [a,b,*], Forough Abbasi [a,b], Stephen H. Bush [a], Ingrid J. Ramirez [a], Beman R. Khulpateea [a], E. Clair McClung [a], Amy L. Berry [a], Nadim Bou Zgheib [a], Hye Sook Chon [a,c], Mian M. Shahzad [a,c], Patricia L. Judson [a,b,c], Robert M. Wenham [a,b,c], Sachin M. Apte [a,c], Anders E. Berglund [d], Anthony M. Magliocco [a,c,e], Johnathan M. Lancaster [f]

[a] Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
[b] Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
[c] Department of Oncologic Sciences, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
[d] Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
[e] Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
[f] Myriad Genetic Laboratories, Salt Lake City, UT 84108, USA

HIGHLIGHTS

- Cisplatin resistance in OVCA cell lines is associated with 9 miRNAs.
- Phenotypically EMT cells are associated with more chemo-resistant cancers.
- *TGF/WNT* and *Development Regulation of EMT* are associated with overall survival.

ARTICLE INFO

Article history:
Received 26 June 2015
Received in revised form 22 December 2015
Accepted 24 December 2015
Available online 28 December 2015

Keywords:
Ovarian cancer
Micro-RNA
Chemoresistance
Epithelial–mesenchymal transition

ABSTRACT

Objectives. Ovarian cancer (OVCA) is the leading cause of mortality among women with gynecologic malignancy, in part due to the development of chemoresistance. We sought to identify micro-RNAs (miRNAs) associated with in vitro development of OVCA chemoresistance that may also represent potential targets for therapy.

Methods. In this study, four OVCA cell lines (A2780CP, A2780S, IGROV1, and OVCAR5) were serially treated with cisplatin in parallel with measurements of miRNA expression changes.

Results. Nine miRNAs were found to be associated with increasing cisplatin resistance (IC_{50}) ($p < 0.01$); however, only 5 of these miRNAs have publically available information. Pathway analysis identified 15 molecular signaling pathways that were represented by genes predicted to be targets of the 5 miRNAs (false discovery rate < 0.05), 11 of which are associated with the epithelial–mesenchymal transition (EMT). Further analysis identified 2 of those pathways as being associated with overall survival in 218 patients with OVCA.

Conclusions. Collectively, this panel of miRNAs associated with in vitro evolution of OVCA cisplatin resistance and the pathways identified to be associated with EMT and overall patient survival provide a framework for further investigations into EMT as a therapeutic target in patients with OVCA.

1. Introduction

Although the rate of diagnosis has been declining for the past 20 years, ovarian cancer (OVCA) remains the leading cause of mortality from gynecologic cancer and the fifth overall for cancer in women [1–4]. It is estimated that 21,290 new cases will be diagnosed in the United States in 2015 and that 14,180 women will die of the disease [5]. The high numbers are in part due to the absence of reliable screening tests for asymptomatic early-stage diagnosis and the fact that many patients will ultimately develop disease that is unresponsive to therapy [1–3,6].

The primary therapy for OVCA is cytoreductive surgery followed by platinum-based chemotherapy. The initial response rate to this primary therapy is nearly 70% [4]. Since 1978, cisplatin, *cis*-[Pt(II)(NH(3))(2)Cl)](PtCl$_2$(NH$_3$)$_2$] or CDDP, has been used as a cancer therapeutic, binding to DNA, forming adducts, and activating apoptosis [7]. The development of cisplatin resistance has long been a

* Corresponding author at: H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
E-mail address: douglas.marchion@moffitt.org (D.C. Marchion).

http://dx.doi.org/10.1016/j.ygyno.2015.12.026
0090-8258/

focus of OVCA research because, despite response to initial platinum-based therapy, the majority of patients with OVCA will ultimately experience chemoresistant relapse and succumb to disease [1–3,6–8]. A multitude of mechanisms result in the development of cisplatin resistance including, increased DNA repair, decreased accumulation of the drug within the cells, and post-translational modification [3,8].

Recently, it has been recognized that micro-RNAs (miRNAs) may influence the development of cisplatin resistance [8]. miRNAs are small (~22 bp) endogenous, non-protein-coding nucleotides that regulate gene expression by base-pairing to the 3′ un-translated region of the target mRNA [3,9–12]. miRNA expression levels vary between normal cells and cancer cell lines and between chemoresistant versus chemosensitive in follicular lymphoma [13], breast cancer [11,14], pancreatic cancer [11], and OVCA [15] cells.

In this study, we evaluated changes in miRNA expression associated with the experimental induction of cisplatin resistance in OVCA cells. Furthermore, in an effort to determine the mechanisms underlying the development of cisplatin resistance, we investigated the molecular signaling pathways represented by miRNA target genes. In doing so, our goal was to find potential targets for treatment or biomarkers for diagnosis and chemotherapy response.

2. Methods

2.1. Cell lines

OVCA cell lines A2780CP, A2780S, IGROV1, and OVCAR5 were kind gifts provided by Dr. Patricia Kruk, Department of Pathology, College of Medicine, University of South Florida (Tampa, FL). All cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Fisher Scientific, Pittsburgh, PA), 1% sodium pyruvate, 1% penicillin/streptomycin (Cellgro, Manassas, VA), and 1% nonessential amino acids (HyClone, Hudson, NH). Mycoplasma testing was performed every 6 months in accordance with the manufacturer's protocol (Lonza, Rockland, ME). The cell lines used in this study have been genotyped by STR profiling to ensure tissue of origin.

2.2. Induction of chemoresistance

We previously reported the in vitro induction of platinum resistance in the OVCA cell lines used for this study [16]. Briefly, cell lines were serially treated with increasing doses of cisplatin with intermittent cell recovery/expansion phases to induce resistance. Three dosing schedules were followed: *schedule A* (3 treatments with 1 μg/mL followed by an additional 3 treatments with 3 μg/mL), *schedule B* (3 treatments with 2 μg/mL followed by an additional 3 treatments with 4 μg/mL), and *schedule C* (3 treatments with 5 μg/mL followed by an additional 3 treatments with 3 μg/mL). After each recovery phase, OVCA cell cisplatin sensitivity was quantified using CellTiter-96 MTS cell viability assays (Fisher Scientific) and in parallel, microRNA (miRNA) expression profiles were evaluated. In total each OVCA cell line underwent 6 treatment-recovery cycles with corresponding miRNA profiling and cisplatin sensitivity quantification.

2.3. MicroRNA isolation and labeling

This process was completed as described by Boren et al. In brief, before the initial treatment and following each recovery phase, Ambion *mir*Vana microRNA isolation kit (Ambion, Austin, TX) was used to extract miRNA. The Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA) was used to assess the quality of total RNA. Using the miRCURY Labeling Kit (Exiqon, Vedbaek, Denmark), 10 μg of Ambion ovarian total RNA and total RNA from each cell line was labeled. Ambion ovarian samples and cell line samples were co-hybridized to printed arrays containing 622 of Invitrogen's NCode multispecies miRNA probes (Invitrogen, Carlsbad, CA), which had 335 unique human miRNAs, and 562 Ambion *mir*Vana miRNA probe set (Ambion, Austin, TX). A GenePix 4000B scanner was used to scan the hybridized arrays and the GenePix Pro software (Molecular Devices, Sunnydale, CA) generated the miRNA expression data [4].

2.4. Statistical analysis

Expression data from the OVCA cell lines were subjected to background correction and normalization using the robust multichip average algorithm [17] and then implemented to the Bioconductor (http://www.bioconductor.org) extensions to the R-statistical programming environment as described previously [18]. Probe sets with expression ranges less than 2-fold (maximum/minimum) and control probes (i.e. AFEX_*probe sets) were excluded from the analysis. miRNAs associated with acquired cisplatin resistance (IC_{50}) were determined using Pearson correlation. A Pearson correlation coefficient, r, less than −0.50 or greater than 0.50 were considered statistically significant. The target genes of significant miRNAs ($p < 0.01$) were determined using the MiRanda database [19].The genes were then analyzed using GeneGo software in order to identify the significantly (false discovery rate < 0.05) represented pathways. Pathways identified in this manner were evaluated for associations with overall survival from OVCA using principal component analysis (PCA) modeling. The first component of the PCA model, PC1, which contains the largest variance, was used to define high versus low pathway score. The median PC1 was used as a threshold when testing pathways for an association with overall survival, using log-rank test, within a publically available clinico-genomic OVCA dataset (n = 218 patients; GSE9891) [16].

3. Results

3.1. Nine miRNAs are associated with the evolution of platinum resistance

Correlation analysis identified 9 miRNAs that were significantly ($p < 0.01$ and Pearson correlation coefficient $-0.50 > r > 0.50$) associated with the IC_{50} of the 4 OVCA cell lines with acquired resistance to cisplatin (Table 1). From the 9 miRNAs, 4 demonstrated a positive correlation (miR-496, miR-485-5p, let-7g, and miR-152) and 5 were negatively correlated (miR-422b, miR-17-3p, miR-520h, miR-27b, and miR-432*).

3.2. miRNAs associated with CDDP resistance dominantly regulate EMT-related genes and pathways

Target genes were identified for 5 of the miRNAs that had been previously determined and made publically available on the MiRanda database (Supplemental Table 1). With these target genes, GeneGo was used to perform pathway analysis, revealing 15 significant (false discovery rate < 0.05) pathways common to 3 or more of the miRNAs (Table 2).

Table 1
Micro-RNA expression correlation with IC_{50} of cisplatin-resistant cell lines.

miRNA	Pearson correlation coefficient, r	*p* value	Correlation
hsa-miR-496	0.68	0.00026	Positive
hsa-miR-485-5p	0.65	0.00060	Positive
hsa-let-7 g	0.56	0.00430	Positive
hsa-miR-422b	−0.55	0.00522	Negative
hsa-miR-152	0.55	0.00587	Positive
hsa-miR-17-3p	−0.54	0.00660	Negative
hsa-miR-520 h	−0.54	0.00697	Negative
hsa-miR-27b	0.53	0.00797	Negative
hsa-miR-432*	−0.52	0.00940	Negative